Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
AssigneesThe John Hopkins University, The Board of Trustees of the Leland Stanford Junior University
InventorsPhilip Arden Beachy, Jynho Kim
Life of this patent
Estimating the term…
Abstract
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in hematopoietic malignancy cells, and determined to be associated with growth and proliferation of the malignancy cells. Accordingly, methods are provided for treating a hematopoietic cell malignancy associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a hematopoietic cell malignancy to treatment with an Hh pathway antagonist.
Claims26
A method of treating hematopoietic cell malignancy in a subject comprising administering to the subject at least one Hh pathway antagonist to reduce Hh pathway activity, wherein the at least one Hh pathway antagonist comprises arsenic trioxide (ATO) or NaAsO2.
A method of ameliorating a hematopoietic cell malignancy in a cell having elevated Hedgehog (Hh) pathway activity in a subject as compared with a subject not having a hematopoietic cell malignancy, comprising administering to the subject an Hh pathway antagonist, thereby ameliorating the hematopoietic cell cancer in the subject, wherein the at least one Hh pathway antagonist comprises arsenic trioxide (ATO) or NaAsO2.
Dependencies are inferred from the claim text.